5 Results for "

BET BD2-IN-3

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "BET BD2-IN-3" in MCE Product Catalog:

Cat. No.: HY-159602
CAS No.: 2677039-66-4
Research Areas:  

Cancer

BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-120000
CAS No.: 1672684-68-2
Purity:  99.62%
Research Areas:  

Inflammation/Immunology Cancer

MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice .
loading...
    loading...
Cat. No.: HY-114504
CAS No.: 1044871-04-6
Purity:  95.00%
Research Areas:  

Inflammation/Immunology

RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models .
loading...
    loading...
Cat. No.: HY-138563
CAS No.: 2138473-38-6
Purity:  99.97%
Research Areas:  

Cancer

GSK973, a chemical probe, is a highly selective, orally bioavailable inhibitor of the BD2s (second bromodomains) of the BET family, with a pIC50 of 7.8 and a pKd of 8.7 for BRD4 BD2. GSK973 displays a 1600-fold selectivity for BRD4 BD2 over BRD4 BD1. GSK973 shows good potency against BRD2 BD2, BRD3 BD2, and BRDT BD2 (pIC50=7.4~7.8; pKd=8.3~8.5) .
loading...
    loading...
Cat. No.: HY-143317
CAS No.: 2933176-32-8
Research Areas:  

Cancer

XY153 (compound 8l) is a BD2-selective BET inhibitor and selectively binds to BRD4 BD2. XY153 binds to BRD4 BD2, BRD3 BD2 and BRD2 BD2 with IC50s of 0.79, 5.31 and 5.09 nM, respectively. XY153 shows potent antiproliferative activity against multiple tumor cell lines. XY153 can be used for the research of acute myeloid leukemia (AML) and cancer .
loading...
    loading...